论文部分内容阅读
日本《国际医学论坛报》1979年12月27日报道:美国南加利福尼亚大学医学研究小组报告,肌酸激酶BB放射免疫测定可作为早期发现前列腺癌的辅助试验,并可用于监测前列腺癌以及其它腺癌病人对于治疗的反应。 1.敏感的肿瘤标志现在肌酸激酶试验作为评价心肌梗塞程度的方法正在深入研究,并发现其对鉴别胸膜渗出液是否恶性也有效。对17名临床各阶段的前列腺癌患者进行了肌酸激酶放射免疫测定(RIA),其中15人显示阳性,阳性中2人经活检发现为良性前列腺肥大,但经耻骨后前列
Japan’s “International Medical Tribune” reported on December 27, 1979: Medical Research Group of the University of Southern California reported that creatine kinase BB radioimmunoassay can be used as an early test for prostate cancer and can be used to monitor prostate cancer and other glands. Cancer patients respond to treatment. 1. Sensitive Tumor Markers Creatine kinase assays are now being studied in depth as a means to assess the extent of myocardial infarction and have also been found to be effective in identifying malignant pleural exudates. Creatine kinase radioimmunoassay (RIA) was performed on 17 clinical prostate cancer patients at each stage. Among them, 15 were positive, and 2 of them were found to be benign prostatic hypertrophy by biopsy, but were postmenopausal forefront.